A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer (NCT05141721)
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus a fluoropyrimidine/bevacizumab alone as assessed by molecular response which is based on changes in circulating tumor (ct)DNA. The primary objective of the Phase 3 portion is to demonstrate clinical efficacy of the regimen as assessed by progression-free survival.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (43 Sites)
Showing the first 25 of 43 sites.
- Banner MD Anderson — Gilbert, Arizona
- Highlands Oncology — Springdale, Arkansas
- U.S.C Norris Cancer Center, Keck School of Medicine, Division of Medical Oncology — Los Angeles, California
- University of California - Irvine (UCI) — Orange, California
- University of California Los Angeles (UCLA) — Santa Monica, California
- Rocky Mountain Cancer Centers - USOR — Denver, Colorado
- Eastern CT Hematology and Oncology Associates (ECHO) — Norwich, Connecticut
- Lynn Cancer Institute - Boca Raton Regional Hospital — Boca Raton, Florida
- University of Miami — Miami, Florida
- Miami Cancer Institute at Baptist Health South Florida (USOR site) — Miami, Florida
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
- Orlando Health — Orlando, Florida
- Advanced Research (Oncology & Hemotology Associates of West Broward) — Tamarac, Florida
- University of Illinois at Chicago — Chicago, Illinois
- University of Chicago — Chicago, Illinois
- Indiana University — Indianapolis, Indiana
- University of Kansas Medical Center — Fairway, Kansas
- Norton Cancer Institute — Louisville, Kentucky
- American Oncology Partners of Maryland, PA — Bethesda, Maryland
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- Astera Cancer Care — East Brunswick, New Jersey
- Summit Health — Florham Park, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Rutgers — New Brunswick, New Jersey
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Neoplasms
- S0820, Adenoma and Second Primary Prevention Trial — Birmingham, Alabama
- MyGI Diet for Colorectal Cancer Prevention — Ann Arbor, Michigan
- Combination Immunotherapy in Colorectal Cancer — Brooklyn, New York
- Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors — Encinitas, California
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... — Bethesda, Maryland
Explore by condition: All Colorectal Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.